These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31984118)

  • 1. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma.
    Galastri FL; Nasser F; Affonso BB; Valle LGM; Odísio BC; Motta-Leal Filho JM; Salvalaggio PR; Garcia RG; de Almeida MD; Baroni RH; Wolosker N
    World J Hepatol; 2020 Jan; 12(1):21-33. PubMed ID: 31984118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning.
    Valle LGM; Cunha MJS; Schmid BP; Falsarella PM; Rezende MB; Felga GEG; Ogawa RE; Garcia RG; Affonso BB; Nasser F; Galastri FL
    Einstein (Sao Paulo); 2023; 21():eAO0307. PubMed ID: 37909650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
    Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
    Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for advanced-stage hepatocellular carcinoma.
    Ye ZD; Zhuang L; Song MC; Yang Z; Zhang W; Zhang JF; Cao GH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2476-2486. PubMed ID: 38994164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.
    Greco G; Cascella T; Facciorusso A; Nani R; Lanocita R; Morosi C; Vaiani M; Calareso G; Greco FG; Ragnanese A; Bongini MA; Marchianò AV; Mazzaferro V; Spreafico C
    World J Radiol; 2017 May; 9(5):245-252. PubMed ID: 28634515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization.
    Odisio BC; Galastri F; Avritscher R; Afonso BB; Segatelli V; Felga GE; Salvalaggio PR; Ensor J; Wallace MJ; Nasser F
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1018-26. PubMed ID: 24149832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
    Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
    Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
    Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
    Mukund A; Bhardwaj K; Choudhury A; Sarin SK
    J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.